The scientist’s investigation covers issues in Hepatocellular carcinoma, Internal medicine, Carcinoma, Radiology and Sorafenib. His studies deal with areas such as Survival rate, Surgery, Pathology and Radiofrequency ablation as well as Hepatocellular carcinoma. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Placebo and Oncology.
His Carcinoma research incorporates themes from Lipiodol, Cancer research, Retrospective cohort study and Prospective cohort study. His Radiology study integrates concerns from other disciplines, such as Differential diagnosis and Pancreas. His work on Lenvatinib as part of general Sorafenib study is frequently linked to In patient, bridging the gap between disciplines.
Internal medicine, Hepatocellular carcinoma, Oncology, Radiology and Gastroenterology are his primary areas of study. Internal medicine is closely attributed to Placebo in his research. His Hepatocellular carcinoma research integrates issues from Carcinoma and Surgery.
He has researched Oncology in several fields, including Pembrolizumab, Cancer, Nivolumab and Regorafenib. His work on Radiofrequency ablation expands to the thematically related Radiology. The concepts of his Gastroenterology study are interwoven with issues in Hepatitis C and Hazard ratio.
His primary scientific interests are in Internal medicine, Hepatocellular carcinoma, Oncology, In patient and Sorafenib. The various areas that Masatoshi Kudo examines in his Internal medicine study include Gastroenterology and Placebo. Masatoshi Kudo works mostly in the field of Hepatocellular carcinoma, limiting it down to topics relating to Pembrolizumab and, in certain cases, Cancer research.
His biological study deals with issues like Nivolumab, which deal with fields such as Ipilimumab. His In patient research spans across into fields like Stent and Radiology. His studies in Sorafenib integrate themes in fields like Regorafenib and Cohort study.
His scientific interests lie mostly in Hepatocellular carcinoma, Internal medicine, Oncology, Sorafenib and Lenvatinib. The Hepatocellular carcinoma study combines topics in areas such as Pembrolizumab, Clinical trial and Carcinoma. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
His research on Oncology also deals with topics like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi.
The Lancet (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito.
The Lancet (2017)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han.
The Lancet (2018)
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.
Michel Claudon;Christoph F. Dietrich;Byung Ihn Choi;David O. Cosgrove.
Ultrasound in Medicine and Biology (2013)
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.
Masao Omata;Laurentius A. Lesmana;Ryosuke Tateishi;Pei Jer Chen.
Hepatology International (2010)
Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
Masatoshi Kudo;Namiki Izumi;Norihiro Kokudo;Osamu Matsui.
Digestive Diseases (2011)
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata;Ann Lii Cheng;Norihiro Kokudo;Masatoshi Kudo.
Hepatology International (2017)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan.
Lancet Oncology (2018)
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).
Masatoshi Kudo;Hobyung Chung;Yukio Osaki.
Journal of Gastroenterology (2003)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson;Shukui Qin;Joong Won Park;Ronnie T.P. Poon.
Journal of Clinical Oncology (2013)
(Impact Factor: 12.43)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: